Drugmaker Cipla on Monday said that it has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback